![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Janssen’s Stelara Approved for Plaque Psoriasis in Children
Janssen’s Stelara Approved for Plaque Psoriasis in Children
August 3, 2020
The FDA has approved Janssen’s Stelara (ustekinumab) for the treatment of children ages 6-11 years old with skin lesions associated with moderate to severe plaque psoriasis.
The approval was based on the results of a phase 3 trial of 44 patients in which 77 percent of participants achieved clear or almost clear skin at week 12 after two doses.
Stelara targets interleukin (IL)-12 and IL-23, two inflammatory cytokines produced by the immune system.
Upcoming Events
-
21Oct